Send to

Choose Destination
Nat Rev Drug Discov. 2006 Mar;5(3):235-46.

An APRIL to remember: novel TNF ligands as therapeutic targets.

Author information

Department of Autoimmunity and Inflammation, ZymoGenetics, Inc. 1201 Eastlake Avenue East, Seattle, Washington 98102, USA.


Since their discovery in 1998, the two TNF family members APRIL and BLyS/BAFF have received increasing attention. In addition to regulating normal B-cell development and immune responses, these molecules might be crucial in a diverse set of diseases, including autoimmunity and cancer. Although more has been published about the general biology of BLyS/BAFF than that of APRIL, many recent articles have described novel APRIL biology. Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center